Papillary Thyroid CarcinomaNCT07062211
Diagnostic Accuracy of Fluorodeoxyglucose-18 PET in the Evaluation of RPTC With Patient's Raised Thyroglobulin Level
An observational study of Papillary Thyroid Carcinoma, run by Superior University at 1 site in Pakistan.
Trial summary
This research will employ cross-sectional analytical to determine diagnostic accuracy of Flourodeoxyglucose-18 Positron Emission Computed Tomography in the evaluation of Recurrent Papillary Thyroid Carcinoma with patient's raised Thyroglobulin level in Lahore. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Papillary Thyroid Carcinoma
- How many people
- 39 participants
- Where
- 1 sitePakistan
- Study dates
- 17 Mar 2025to 1 Mar 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This research will employ cross-sectional analytical to determine diagnostic accuracy of Flourodeoxyglucose-18 Positron Emission Computed Tomography in the evaluation of Recurrent Papillary Thyroid Carcinoma with patient's raised Thyroglobulin level
Who may be able to join
- Patients include both male and female from 18years to 80years
- Patients presented with raised thyroglobulin
- Patients with suspected diagnosis of recurrent papillary thyroid carcinoma
Who cannot join
- Patients exclude both male and female below 18years and above 80years
- All the patients presented with carcinoma other than papillary carcinoma.
- All the patients with normal thyroglobulin level.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Diagnostic Accuracy of Flourodeoxyglucose-18 Positron Emission Computed Tomography in the Evaluation of Recurrent Papillary Thyroid Carcinoma With Patient's Raised Thyroglobulin Level in Lahore
This research will employ cross-sectional analytical to determine diagnostic accuracy of Flourodeoxyglucose-18 Positron Emission Computed Tomography in the evaluation of Recurrent Papillary Thyroid Carcinoma with patient's raised Thyroglobulin level in Lahore.
- Conditions
- Papillary Thyroid Carcinoma
- Medical subject headings
- Thyroid Cancer, Papillary
What is being measured
The primary outcome is the main question the study is designed to answer.
Nominal self admsinitered questioner
Scoring in a nominal scale involves assigning a unique numerical or symbolic code to each category. For instance, in a gender survey, you might code male as "1" and female as "2." However, these codes are purely for identification and do not imply any order or magnitude
Measured: 12 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2025
- Study start17 Mar 2025
- Primary completion1 Sep 2025 (estimated)
- Study completion1 Mar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Papillary Thyroid CarcinomaStudies of the same condition, open and under way.
- More trials run by Superior UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 39 participants (actual)
Sponsor and investigators
- Lead sponsor
- Superior University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Muhammad Naveed Babur, Superior University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07062211
- Sponsor's protocol ID
- MSAHSW/Batch-Fall23/908
- Status last verified
- Jul 2025
- First submitted
- 24 Jun 2025
- Last updated
- 14 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diagnostic Accuracy of Flourodeoxyglucose-18 Positron Emission Computed Tomography in the Evaluation of Recurrent Papillary Thyroid Carcinoma With Patient's Raised Thyroglobulin Level in Lahore
- ClinicalTrials.gov ID
- NCT07062211
- Acronym / sponsor ID
- MSAHSW/Batch-Fall23/908
- Conditions
- Papillary Thyroid Carcinoma
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 39 participants (actual)
- Lead sponsor
- Superior UniversityUniversity, hospital or other
- Study start
- 17 Mar 2025 (actual)
- Primary completion
- 1 Sep 2025 (estimated)
- Study completion
- 1 Mar 2026 (estimated)
- First posted
- 14 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This research will employ cross-sectional analytical to determine diagnostic accuracy of Flourodeoxyglucose-18 Positron Emission Computed Tomography in the evaluation of Recurrent Papillary Thyroid Carcinoma with patient's raised Thyroglobulin level in Lahore.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This research will employ cross-sectional analytical to determine diagnostic accuracy of Flourodeoxyglucose-18 Positron Emission Computed Tomography in the evaluation of Recurrent Papillary Thyroid Carcinoma with patient's raised Thyroglobulin level
Key inclusion criteria (3 listed)
- Patients include both male and female from 18years to 80years
- Patients presented with raised thyroglobulin
- Patients with suspected diagnosis of recurrent papillary thyroid carcinoma
Key exclusion criteria (3 listed)
- Patients exclude both male and female below 18years and above 80years
- All the patients presented with carcinoma other than papillary carcinoma.
- All the patients with normal thyroglobulin level.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Nominal self admsinitered questioner
Time frame: 12 Months
Scoring in a nominal scale involves assigning a unique numerical or symbolic code to each category. For instance, in a gender survey, you might code male as "1" and female as "2." However, these codes are purely for identification and do not imply any order or magnitude
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for Papillary Thyroid Carcinoma
Recruiting
Active Surveillance of Papillary Thyroid Microcarcinoma
Papillary Thyroid Microcarcinoma
RecruitingObservational study
Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY
Papillary Thyroid Cancer
Not yet recruitingObservational study
Serum Treg/Th17-Related Cytokines and Systemic Inflammatory Indices in Differentiated Thyroid Cancer
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Carcinoma
RecruitingObservational study
Studies on Tumors of the Thyroid
Hurthle Cell Thyroid Cancer, Tall Cell Variant Thyroid Cancer
Active, not recruitingPhase 3
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Differentiated Thyroid Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Papillary Thyroid Carcinoma, run by Superior University at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 14 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Nominal self admsinitered questioner (time frame: 12 Months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2025.